ALLOAllogene Therapeutics, Inc.
Allogene Therapeutics, Inc. a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer and autoimmune diseases. It develops a pipe…
Industry Peers
Biotechnology| Headline | Source | Time |
|---|---|---|
Older | ||
 Allogene (ALLO) Q2 2026 Earnings Call Transcript Cema-cel hit 58.3% MRD negativity in ALPHA3 with zero treatment hospitalizations. | ||
 Is Allogene Therapeutics (ALLO) Stock Outpacing Its Medical Peers This Year? Here is how Allogene Therapeutics (ALLO) and Brainsway Ltd. Sponsored ADR (BWAY) have performed compared to their sector so far this year. | ||
 Allogene Therapeutics' Q2 Earnings Beat Estimates on Lower R&D Costs ALLO narrows its Q2 loss as R&D costs fall, while a stronger cash position extends its runway into 2029. | ||
Allogene Therapeutics Remains Attractive Given Valuation, Clinical Strategy, RBC Says Allogene Therapeutics (ALLO) remains attractive given its undemanding valuation and differentiated c | MMT Newswires | |
 Allogene Therapeutics, Inc. Q2 2026 Earnings Call Summary Moby summary of Allogene Therapeutics, Inc.'s Q2 2026 earnings call | ||
Allogene Therapeutics Inc (ALLO) (Q2 2026) Earnings Call Highlights: RMAT Designation and Rapid ... Allogene Therapeutics Inc (ALLO) advances its allogeneic CAR-T pipeline with key regulatory milestones and strong trial momentum, while navigating solid tumor challenges and competitive pressures. | ||
 Allogene Therapeutics Q2 Earnings Call Highlights Allogene Therapeutics (NASDAQ:ALLO) outlined progress across its clinical pipeline during its second-quarter 2026 conference call, highlighting expanded enrollment infrastructure for its pivotal ALPHA3 lymphoma study, recent FDA designations for cema-cel, published renal cell carcinoma data for ALLO | ||
IInsider Monkey | ||
IInsider Monkey | ||